Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer

Phase 2

Completed

Conditions: Urologic Neoplasms

Interventions: Drug: Trastuzumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2005-09-08

Last Posted Date: 2015-01-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 33

Registration Number: NCT00151034

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
🇺🇸
California City of Hope National Medical Group, Duarte, California, United States

and more 8 locations

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: CP-751,871
Drug: paclitaxel
Drug: carboplatin
Drug: erlotinib

First Posted Date: 2005-09-07

Last Posted Date: 2013-10-30

Lead Sponsor: Pfizer

Target Recruit Count: 282

Registration Number: NCT00147537

Locations: 🇪🇸
Pfizer Investigational Site, Sevilla, Spain

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Stage I Breast Cancer
Stage II Breast Cancer

First Posted Date: 2005-09-07

Last Posted Date: 2023-08-02

Lead Sponsor: Harold J. Burstein, MD, PhD

Target Recruit Count: 135

Registration Number: NCT00146562

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 3 locations

Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer
Stage IV Breast Cancer

First Posted Date: 2005-09-07

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 250

Registration Number: NCT00146549

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer

Phase 2

Terminated

Conditions: Cervical Cancer

Interventions: Biological: recombinant interferon alpha-2b
Drug: isotretinoin
Drug: paclitaxel

First Posted Date: 2005-08-30

Last Posted Date: 2013-11-20

Lead Sponsor: University of Medicine and Dentistry of New Jersey

Target Recruit Count: 33

Registration Number: NCT00138151

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
UMDNJ University Hospital, Newark, New Jersey, United States
🇺🇸
Carol G. Simon Cancer Center at Morristown Memorial Hospital, Morristown, New Jersey, United States

and more 3 locations

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2005-08-29

Last Posted Date: 2013-02-18

Lead Sponsor: Harold J. Burstein, MD, PhD

Target Recruit Count: 41

Registration Number: NCT00136539

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2005-08-26

Last Posted Date: 2015-01-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 68

Registration Number: NCT00136175

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel

Completed

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: doxorubicin
Drug: paclitaxel

First Posted Date: 2005-08-19

Last Posted Date: 2016-07-25

Lead Sponsor: Duke University

Target Recruit Count: 94

Registration Number: NCT00131963

Locations: 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States

Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2005-08-12

Last Posted Date: 2016-06-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 62

Registration Number: NCT00129727

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Fluorouracil
Drug: paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2005-08-12

Last Posted Date: 2023-03-06

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 1289

Registration Number: NCT00129922

Locations: 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸
Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸
Hospital Universitario Puerto Real, Puerto Real, Cádiz, Spain

and more 61 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy